StockData
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Taysha Gene Therapies, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.94+0.32 (+8.84%)

Close on Oct 19, 2026

Market cap
$1.45B
P/E (TTM)
–
Dividend yield
–

Taysha Gene Therapies, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Taysha Gene Therapies does not break out revenue by segment, region or product in the tagged data of its filings for this period type.